Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Two scientists in a lab

There is currently a lack of available treatments that can prevent or modify the progression of neurodegenerative disorders like Alzheimer's disease and Parkinson's disease, which affect millions of people in Europe. Despite robust research efforts to accelerate biomarker discovery, there are few secure, accessible ways for clinical samples and data to be discovered and shared within the research community.

'Alzheimer's and Parkinson's cost millions of lives and will create an estimated economic burden in Europe of €267 billion by 2030,' said project co-Coordinator Pieter Jelle Visser, Associate Professor at the University of Maastricht. 'EPND will answer this massive challenge with a solution on the same scale, bringing together teams, samples and data from across the continent.'

Professor Michele Hu is a Co-Investigator on the project, and UK lead for the Parkinson's disease biomarker collection.

The development of effective treatments requires biomarkers for early detection of disease in individuals, for assessing treatment efficacy, and for patient stratification. Thanks to funding from the Innovative Medicines Initiative (IMI), EPND will begin a five-year effort to establish a self-sustaining network that will support the discovery, harmonization, storage and analysis of high-quality clinical samples and data from neurodegenerative disease research.

Beyond establishing the network, the project aims to create agreed principles to enable access to samples and data, establish fair and transparent governance and processes, and achieve self-sustainability after five years. When complete, it will create a new entity supported by some of the most prestigious medical and research organisations in the EU. This public-private partnership will accelerate and simplify innovation in the areas of R&D, regulatory, clinical and healthcare practices.

Similar stories

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

COVID-19 infection has greater risk than vaccines of causing very rare neurological events

Research reveals risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.

New genetic diagnosis technology for eye disease receives major funding award

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.